Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
January 18, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE...
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
November 30, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
October 26, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
October 14, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing...
Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
September 09, 2021 12:46 ET
|
Clarus Therapeutics, Inc.; Blue Water Acquisition Corp.
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
July 15, 2021 09:00 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019 14:04 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...